How Ozempic, Wegovy and Mounjaro Protect Your Heart — Not Just Your Waistline

A New Era in Heart & Metabolic Health

Over the past few years, injectable medications like Ozempic
, Wegovy
, and Mounjaro
have revolutionised how we approach weight loss and type 2 diabetes.

But beyond blood sugar and body weight, these treatments are now being recognised for something far more significant — their ability to protect the heart
.

At The Wright Practice
in Harley Street, we focus on proactive and longevity-based healthcare
. Understanding how these medicines work — and who they benefit most — helps us tailor truly individual health plans.

Ozempic® (Semaglutide 0.5–1.0 mg weekly): Diabetes and Heart Protection

Ozempic was originally developed for type 2 diabetes, but large studies have shown it lowers the risk of serious heart events
such as heart attack and stroke.

The evidence:

The SUSTAIN-6
trial (published in the New England Journal of Medicine
) found that people with type 2 diabetes taking Ozempic had:

• 25% fewer major cardiovascular events
  than those on placebo
• Fewer non-fatal strokes and heart attacks
• Benefits that appeared within the first year and strengthened over time

✅ Takeaway:
Ozempic not only helps regulate blood sugar and support weight management — it also protects against cardiovascular disease
in those already at risk.

Wegovy® (Semaglutide 2.4 mg weekly): Heart Protection Without Diabetes

Wegovy, which contains the same active ingredient as Ozempic but at a higher dose, is prescribed for weight management.

Until recently, no weight-loss medicine had been proven to actually reduce the risk of heart attack or stroke
. That changed with the landmark SELECT trial (2023)
.

The evidence:

• Over 17,000 adults with obesity (BMI ≥27) and established heart disease but no diabetes
  were studied.
• Those taking Wegovy had a 20% lower risk of major heart events
  (heart attack, stroke, or heart-related death).
• Benefits extended beyond weight loss — participants also saw improvements in blood pressure, cholesterol, and inflammation.

✅ Takeaway:
Wegovy is now the first weight-loss medication approved by the FDA to reduce cardiovascular risk
. For patients with heart disease and excess weight, this is a major step forward in preventive medicine.

Mounjaro® (Tirzepatide): Dual Hormone Innovation

Mounjaro is slightly different — it acts on both GLP-1 and GIP receptors
, offering powerful effects on glucose control and weight reduction.

The evidence so far:

The ongoing SURPASS-CVOT
study compared Mounjaro with dulaglutide (another GLP-1 medicine). Early data suggest:

• Mounjaro is at least as safe for the heart
  as dulaglutide
• There may be a trend toward fewer heart events, but full results are still being analysed

✅ Takeaway:
Mounjaro already appears heart-safe
, and upcoming data may confirm additional cardiovascular benefits similar to semaglutide.

What This Means for You

These medicines aren’t simply about appearance or numbers on a scale.
They’re part of a whole-body, heart-protective strategy
that can:

• Reduce inflammation and oxidative stress
• Improve insulin sensitivity
• Lower blood pressure and cholesterol
• Support sustainable, long-term cardiovascular health

At The Wright Practice
, we integrate these treatments as part of a comprehensive longevity plan
— including nutrition, exercise, hormone optimisation, and advanced blood testing.

In Summary

MedicationMain StudyWho It HelpedHeart ImpactOzempic®
SUSTAIN-6Type 2 diabetes↓ 25% heart attacks, strokes, CV deathsWegovy®
SELECTObesity + CVD (no diabetes)↓ 20% major heart events (FDA-approved)Mounjaro®
SURPASS-CVOTType 2 diabetesHeart-safe, results pending

The Wright Practice Approach

We believe in treating the whole person
, not just one marker.
Whether your goal is longevity, weight optimisation, or cardiovascular prevention, our personalised approach combines the best of modern medical science and lifestyle medicine.

Book a consultation
to discuss whether a GLP-1 or GIP treatment could support your long-term health goals.